<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002364</url>
  </required_header>
  <id_info>
    <org_study_id>238C</org_study_id>
    <secondary_id>CNAA 2003</secondary_id>
    <nct_id>NCT00002364</nct_id>
  </id_info>
  <brief_title>A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs</brief_title>
  <official_title>An Exploratory Study of the Antiretroviral Activity of 1592U89 When Administered in Combination With Other Specific Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in NRTI Experienced Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To obtain preliminary evidence of antiretroviral activity of 1592U89 when administered in&#xD;
      combination with other specific NRTI agents in NRTI experienced patients and to assess the&#xD;
      safety and tolerance of multiple oral doses of 1592U89 when administered in combination with&#xD;
      specific marketed NRTIs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will all receive oral doses of 1592U89 in combination with protocol specific current&#xD;
      antiretroviral therapy. The treatment groups will be assigned based on each subject's&#xD;
      previous NRTI experience.&#xD;
&#xD;
      The study medication is self administered and all evaluations will be performed on an&#xD;
      outpatient basis. Patients will be seen at day 0 and weeks 2, 4, 12, 16, 20 and 24.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  CD4+ cell count &gt;= 100 /mm3.&#xD;
&#xD;
          -  Plasma HIV RNA &gt;= 30,000 copies/ml.&#xD;
&#xD;
          -  Study participants may be recruited from all clinical categories, provided they do not&#xD;
             meet any of the exclusion criteria.&#xD;
&#xD;
          -  Parent or legal guardian to sign written, informed consent for patients under the age&#xD;
             of 18.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with any of the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Patients with active or ongoing AIDS-defining opportunistic infection or disease.&#xD;
             NOTE:&#xD;
&#xD;
          -  For this study, a CD4+ cell count &lt;= 200 cells/mm3 in the absence of any other AIDS&#xD;
             defining indicator condition is not considered an AIDS defining event.&#xD;
&#xD;
          -  Malabsorption syndrome or other gastrointestinal dysfunction that might interfere with&#xD;
             drug absorption.&#xD;
&#xD;
          -  Patients with life threatening infection or other serious medical conditions whose&#xD;
             participation may compromise patient safety.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Treatment with cytotoxic chemotherapeutic agents within the 24 weeks of the study.&#xD;
&#xD;
          -  Patients receiving other investigational drugs.&#xD;
&#xD;
          -  Foscarnet therapy or therapy with other agents with documented activity against HIV in&#xD;
             vitro.&#xD;
&#xD;
          -  Treatment with immunomodulators.&#xD;
&#xD;
          -  Patients on methadone.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Treatment with radiation therapy within the 24 weeks of the study. NOTE:&#xD;
&#xD;
          -  Localized radiation therapy may be permitted following consultation with the sponsor.&#xD;
&#xD;
        Patients with any of the following prior conditions are excluded:&#xD;
&#xD;
          -  Subjects with a history of lymphoma.&#xD;
&#xD;
          -  Subjects with a history of clinically apparent pancreatitis or hepatitis within the&#xD;
             last 6 months.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Treatment with any antiretroviral therapy with NRTIs (alone or in combination) other&#xD;
             than those defined for each treatment group.&#xD;
&#xD;
          -  Treatment with any non-nucleoside RT inhibitors or protease inhibitors.&#xD;
&#xD;
          -  Treatment with cytotoxic chemotherapeutic agents within 1 month prior to study entry.&#xD;
&#xD;
          -  Investigational HIV vaccine within the past 3 months.&#xD;
&#xD;
          -  Immunomodulating agents such as systematic corticosteroids, interleukins, thalidomide,&#xD;
             anticytokine agents, anti-oxidants or interferons within 1 month of study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Treatment with radiation therapy within 1 month of entry.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Patients with current alcohol or illicit drug use that, in the opinion of the principal&#xD;
        investigator, may interfere with the patient's ability to comply with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Marin County Specialty Clinic</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kraus Med Partners</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ViRx Inc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IDC Research Initiative</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Broward Hosp District</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Kentucky Med Ctr</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 1997</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

